The Rheumatologist
COVID-19 News
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Systemic Lupus Erythematosus Resource Center
      • Rheumatoid Arthritis Resource Center
      • Gout Resource Center
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Managing Myositis in 3 Different Scenarios

Managing Myositis in 3 Different Scenarios

February 18, 2018 • By Susan Bernstein

  • Tweet
  • Email
Print-Friendly Version / Save PDF

“Look for drug interactions as well. Perhaps the statin wasn’t the problem at all, but the patient was on another drug that blocked the C3 or C4 pathway and raised the level of statin in the blood, causing the hyperCKemia or muscle symptoms,” said Dr. Aggarwal.

You Might Also Like
  • Myositis AutoantibodiesTriggered by Statins
  • Tips for Myositis Management
  • Myositis Autoantibodies as Biomarkers
Explore This Issue
February 2018
Also By This Author
  • 2014 ACR/ARHP Annual Meeting: Rheumatologic Research Uncovers Clues to Therapies

Both muscle biopsy and electromyography may help show why CK is elevated, but patients may choose to avoid these tests if their symptoms are tolerable. Some neuromuscular disorders have a benign course.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Immune-Mediated Necrotizing Myopathy

Recent findings on immune-mediated necrotizing myopathy (IMNM), an idiopathic inflammatory myopathy, include specific biomarkers, said Eleni Tiniakou, MD, an instructor of medicine at Johns Hopkins School of Medicine in Baltimore. Distinct from dermatomyositis or polymyositis, IMNM is “a third pattern we see in muscle biopsies: necrotizing myopathy, where we see prominent myofiber necrosis, degeneration and regeneration, and sparse inflammation,” she said. Two myositis-specific autoantibodies, anti-SRP and anti-HMCGR, play a role in IMNM.3

IMNM patients may have subacute or insidious disease onset, symmetrical proximal muscle weakness, elevated CK, and at least one of the following clinical features: irritable myopathy, edema on MRI or a myositis-specific autoantibody. Muscle biopsy confirms diagnosis.4

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Women with IMNM often have the anti-SRP form, which has severe, rapid progression. Patients have highly elevated CK, minimal extramuscular manifestations, such as Raynaud’s phenomenon or inter­stitial lung disease (ILD), and may have dysphagia or cardiac involvement. Childhood- or early adulthood-onset predicts worse outcomes for those with anti-SRP IMNM, and patients may be very resistant to treatment, she said.

Patients with anti-HMCGR IMNM are female in up to 73% of cases, have severe muscle weakness, highly elevated CK, minimal extramuscular manifestations and may have dysphagia, but statin exposure is the most common culprit. Percentages of anti-HMCGR IMNM patients who have used statins are far lower in Asian studies than those conducted in the West. Patients in Asian cohorts tend to be younger overall, but they may also be exposed to statins in foods rather than prescription medication, said Dr. Tiniakou.

Statins were first described in fungi, and “mushrooms are a very common ingredient in Chinese and Japanese cuisine. Red yeast rice, a traditional Chinese medicinal product, contains high levels of statins, as does pu-erh tea, which is manufactured in China and has become popular for its cholesterol-lowering properties.” Younger age at diagnosis also tends to worsen anti-HMCGR IMNM outcomes, and this myopathy is also treatment resistant.

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE

Immunoprecipitation is used to detect both autoantibodies in IMNM patients. Commercial ELISA tests are also available, but these are costly and may result in false positives, she said. Use ELISA tests only in patients with CK levels over 1,000 for more than eight weeks, or those who have persistent muscle weakness, she said.5 Combination therapy is the best approach for IMNM, usually prednisone and either azathioprine, mycophenolate mofetil or methotrexate.

Lung Disease in Myositis

Lung disease is treatable in some myositis patients, but may be life threatening in others, said Paul F. Dellaripa, MD, associate professor of medicine at Harvard Medical School and a rheumatologist at Brigham and Women’s Hospital in Boston.

Pages: 1 2 3 4 | Single Page

Filed Under: Meeting Reports, Soft Tissue Pain Tagged With: ACR/ARHP Annual Meeting, creatine, Interstitial Lung Disease, myositis, necrotizing myopathyIssue: February 2018

You Might Also Like:
  • Myositis AutoantibodiesTriggered by Statins
  • Tips for Myositis Management
  • Myositis Autoantibodies as Biomarkers
  • Statins Linked to Idiopathic Inflammatory Myositis

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

American College of Rheumatology

Visit the official website for the American College of Rheumatology.

Visit the ACR »

Meeting Abstracts

Browse and search abstracts from the ACR Convergence and ACR/ARP Annual Meetings going back to 2012.

Visit the Abstracts site »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2022 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)